|
|
Blood, 1 March 2005, Vol. 105, No. 5, pp. 2132-2134.
Prepublished online as a Blood First Edition Paper on November 23, 2004; DOI 10.1182/blood-2004-01-0366.
 Previous Article | Next Article 
Submitted January 29, 2004
Accepted September 20, 2004
Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of multiple myeloma patients
Carmen Choi, Mathias Witzens, Marianna Bucur, Markus Feuerer, Nora Sommerfeldt, Andreas Trojan, Anthony Ho, Volker Schirrmacher, Hartmut Goldschmidt, and Philipp Beckhove*
Tumor Immunology Program, The German Cancer Research Center, Heidelberg, Germany
Department of Hematology and Oncology, The University Hospital, Heidelberg, Germany
Department of Experimental Rheumatology, Medical Clinic, Charite, Humboldt University, Berlin, Germany
Department of Oncology, University Hospital, Zurich, Switzerland
* Corresponding author; email: p.beckhove{at}dkfz.de.
Multiple myeloma (MM) is one of the most common hematological malignancies. Despite extensive therapeutical approaches, cures remain rare exceptions. An important issue for future immunological treatments is the characterisation of appropriate tumor associated antigens. Recently, a highly glycosylated mucin, MUC1 was detected on a majority of multiple myeloma cell lines. We analysed bone marrow and peripheral blood of 68 HLA-A2 positive myeloma patients for presence and functional activity of CD8 T cells specific for the MUC1 derived peptide LLLLTVLTV. 44% of the MM patients contained elevated frequencies of MUC1 specific CD8 T cells in freshly isolated samples from PB or BM compared to corresponding samples from healthy donors. BM residing T cells possesed a higher functional capacity upon specific reactivation than PB derived T cells with regard to IFN-gamma secretion, perforin production and cytotoxicity.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
N-T Ngo, C Brodie, C Giles, D Horncastle, M Klammer, I A Lampert, A Rahemtulla, and K N Naresh
The significance of tumour cell immunophenotype in myeloma and its impact on clinical outcome
J. Clin. Pathol.,
November 1, 2009;
62(11):
1009 - 1015.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Domschke, F. Schuetz, Y. Ge, T. Seibel, C. Falk, B. Brors, I. Vlodavsky, N. Sommerfeldt, H.-P. Sinn, M.-C. Kuhnle, et al.
Intratumoral Cytokines and Tumor Cell Biology Determine Spontaneous Breast Cancer-Specific Immune Responses and Their Correlation to Prognosis
Cancer Res.,
November 1, 2009;
69(21):
8420 - 8428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Melenhorst, P. Scheinberg, P. K. Chattopadhyay, E. Gostick, K. Ladell, M. Roederer, N. F. Hensel, D. C. Douek, A. J. Barrett, and D. A. Price
High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow
Blood,
March 5, 2009;
113(10):
2238 - 2244.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Umansky, O. Abschuetz, W. Osen, M. Ramacher, F. Zhao, M. Kato, and D. Schadendorf
Melanoma-Specific Memory T Cells Are Functionally Active in Ret Transgenic Mice without Macroscopic Tumors
Cancer Res.,
November 15, 2008;
68(22):
9451 - 9458.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Kalli, C. J. Krco, L. C. Hartmann, K. Goodman, M. J. Maurer, C. Yu, E. M. Johnson, C. L. Erskine, M. L. Disis, P. J. Wettstein, et al.
An HLA-DR-Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2-Specific Immunity in Patients with Cancer
Cancer Res.,
June 15, 2008;
68(12):
4893 - 4901.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Webster, R. H. Thompson, K. J. Harris, X. Frigola, S. Kuntz, B. A. Inman, and H. Dong
Targeting Molecular and Cellular Inhibitory Mechanisms for Improvement of Antitumor Memory Responses Reactivated by Tumor Cell Vaccine
J. Immunol.,
September 1, 2007;
179(5):
2860 - 2869.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Condomines, D. Hose, P. Raynaud, M. Hundemer, J. De Vos, M. Baudard, T. Moehler, V. Pantesco, M. Moos, J.-F. Schved, et al.
Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis
J. Immunol.,
March 1, 2007;
178(5):
3307 - 3315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Grube, S. Moritz, E. C. Obermann, K. Rezvani, A. Mackensen, R. Andreesen, and E. Holler
CD8+ T cells Reactive to Survivin Antigen in Patients with Multiple Myeloma
Clin. Cancer Res.,
February 1, 2007;
13(3):
1053 - 1060.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Zhang, H. Dong, W. Lin, S. Voss, L. Hinkley, M. Westergren, G. Tian, D. Berry, D. Lewellen, R. G. Vile, et al.
Human Bone Marrow: A Reservoir for "Enhanced Effector Memory" CD8+ T Cells with Potent Recall Function
J. Immunol.,
November 15, 2006;
177(10):
6730 - 6737.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Goodyear, K. Piper, N. Khan, J. Starczynski, P. Mahendra, G. Pratt, and P. Moss
CD8+T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden
Blood,
December 15, 2005;
106(13):
4217 - 4224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jalili, S. Ozaki, T. Hara, H. Shibata, T. Hashimoto, M. Abe, Y. Nishioka, and T. Matsumoto
Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma
Blood,
November 15, 2005;
106(10):
3538 - 3545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. H. Schmitz-Winnenthal, C. Volk, K. Z'graggen, L. Galindo, D. Nummer, Y. Ziouta, M. Bucur, J. Weitz, V. Schirrmacher, M. W. Buchler, et al.
High Frequencies of Functional Tumor-Reactive T Cells in Bone Marrow and Blood of Pancreatic Cancer Patients
Cancer Res.,
November 1, 2005;
65(21):
10079 - 10087.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
